These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 33000173)

  • 1. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
    Jin S; Shang Z; Wang W; Gu C; Wei Y; Zhu Y; Yang C; Zhang T; Zhu Y; Zhu Y; Wu J; Ye D
    J Immunother; 2023 May; 46(4):154-159. PubMed ID: 37017991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
    Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
    Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and prognostic significance of PD-L1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study.
    Wusiman D; Guo L; Li L; Zhang X; Zhao X; An Z; Huang Z; Zhang Y; Li Z; Ying J; Wei M; Li W; An C
    J Endocrinol Invest; 2024 Jan; 47(1):91-100. PubMed ID: 37464189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
    Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
    Front Immunol; 2019; 10():835. PubMed ID: 31134049
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
    Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
    Anderson AC; Joller N; Kuchroo VK
    Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
    Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
    J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
    Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
    Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
    [No Abstract]   [Full Text] [Related]  

  • 13. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC
    Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma.
    Ledderose S; Ledderose C; Ledderose GJ
    Pathol Res Pract; 2024 Aug; 260():155468. PubMed ID: 39018929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
    Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
    Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of immune checkpoints in T cells of esophageal cancer patients.
    Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
    Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
    Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
    Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.